PanDrugs

Here, we introduce PanDrugs2, a major upgrade of PanDrugs that, in addition to somatic variant analysis, supports a new integrated multi-omics analysis which simultaneously combines somatic and germline variants, copy number variation and gene expression data. Moreover, PanDrugs2 now considers cancer genetic dependencies to extend tumor vulnerabilities providing therapeutic options for untargetable genes. Importantly, a novel intuitive report to support clinical decision-making is generated. PanDrugs database has been updated, integrating 23 primary sources that support >74K drug-gene associations obtained from 4642 genes and 14 659 unique compounds. The database has also been reimplemented to allow semi-automatic updates to facilitate maintenance and release of future versions.我们在此介绍PanDrugs2——PanDrugs的重大升级版本。除体细胞变异（somatic variant）分析外，其新增一体化多组学分析（multi-omics analysis）功能，可同时整合体细胞变异、生殖系变异（germline variant）、拷贝数变异（copy number variation）与基因表达数据。此外，PanDrugs2现已纳入癌症遗传依赖性数据，以拓展肿瘤脆弱性覆盖范畴，为此前难以靶向的基因提供治疗方案选择。尤为关键的是，该工具还生成了全新的直观报告，用于辅助临床决策制定。本次升级同步更新了PanDrugs数据库，整合23个原始数据源，涵盖来自4642个基因与14659种独特化合物的逾7.4万条药物-基因关联（drug-gene association）数据。此外，该数据库已完成架构重构，支持半自动更新，以简化后续版本的维护与发布流程。

搜集汇总

背景与挑战

背景概述

PanDrugs2是PanDrugs的主要升级版本，支持整合多组学数据（如体细胞和种系变异、拷贝数变异和基因表达）以优先考虑抗癌治疗。该平台基于来自23个主要来源的74,087个药物-靶点关联，通过计算药物评分和基因评分来生成临床决策支持报告。